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Edited by Veli-Pekka LehtoAbstract In Mv1Lu cells, insulin partially reverses transform-
ing growth factor-b1 (TGF-b1) growth inhibition in the presence
of a5b1 integrin antagonists. TGF-b1 appears to induce phos-
phorylation of IRS-2 in these cells; this is inhibited by a TGF-b
antagonist known to reverse TGF-b growth inhibition. Stable
transfection of 32D myeloid cells (which lack endogenous IRS
proteins and are insensitive to growth inhibition by TGF-b1) with
IRS-1 or IRS-2 cDNA confers sensitivity to growth inhibition by
TGF-b1; this IRS-mediated growth inhibition can be partially
reversed by insulin in 32D cells stably expressing IRS-2 and the
insulin receptor (IR). These results suggest that growth inhibition
by TGF-b1 involves IRS proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transforming growth factor-b (TGF-b) is a family of
structurally homologous dimeric proteins (three mammalian
isoforms: TGF-b1, TGF-b2 and TGF-b3) [1,2]. TGF-b is a
bifunctional growth regulator; it inhibits growth of most cell
types, including epithelial, endothelial and hematopoietic cells,
but stimulates growth of mesenchymal cells such as ﬁbroblasts
and osteoblasts [3]. In addition to its growth regulatory ac-
tivities, TGF-b exhibits other biological activities, including
regulation of extracellular matrix synthesis, chemotaxis, angi-
ogenesis and diﬀerentiation of several cell lineages. It has
been implicated in many pathophysiological processes in-
cluding wound repair, tissue ﬁbrosis, immunosuppression and
morphogenesis [4].
Two of its prominent biological activities are cell growth
inhibition and transcriptional activation of extracellular matrix
synthesis-related genes. Accumulating evidence indicates that
these two activities are uncoupled in many human carcinoma
cells [5–10]. Such cells fail to respond to growth inhibition by
TGF-b but exhibit TGF-b-mediated transcriptional activation
of extracellular matrix synthesis-related genes; this is known toq This work was supported by National Institutes of Health Grant
CA 38808.
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doi:10.1016/j.febslet.2004.03.082be primarily mediated by the type I/type II TGF-b receptor
(TbR-I/TbR-II) heterocomplex in the cell systems studied so
far [11,12]. The separation of these activities implies that sig-
naling pathways other than the TbR-I/TbR-II signaling cas-
cade are involved [10,13–16]. Several signaling cascades, which
are diﬀerent from the TbR-I/TbR-II heterocomplex/Smad2/3/4
signaling cascade, have been shown to be involved in the
growth inhibitory response to TGF-b [10,13–16]. However, it is
not known which TGF-b receptor types mediate the activation
of these signaling cascades because most of the cell systems used
for the investigations express other TGF-b receptor types in
addition to TbR-I and TbR-II.
The type V TGF-b-receptor (TbR-V) is a high molecular
weight non-proteoglycan membrane protein and co-expresses
with TbR-I, TbR-II and TbR-III in most cell types [17–21].
Many human carcinoma cells express little or noTbR-V [19–22],
and their growth is not inhibited by TGF-b. This suggests that
TbR-V may be involved in the growth inhibitory response to
TGF-b and that its loss may contribute to the malignant phe-
notype of these human carcinoma cells. The identiﬁcation of
TbR-V as the IGFBP-3 receptor, which mediates the IGF-
independent (TGF-b peptide antagonist sensitive) growth
inhibitory response to IGFBP-3, has highlighted the likely im-
portance of TbR-V in mediating the growth inhibitory response
[6,21,22]. TbR-V was also recently found to be identical to low
density lipoprotein receptor-related protein-1 (LRP-1) [23].
Several lines of evidence have revealed that TbR-V/LRP-1 is
required for growth inhibition by IGFBP-3 andTGF-b [23]. The
ﬁnding that TbR-V is identical to LRP-1 has disclosed previ-
ously unreported growth regulatory function of LRP-1. LRP-1
is best known as an endoctyic receptor [24,25]. Increasing evi-
dence indicates thatLRP-1 is also capable ofmediating signaling
[24,25]. However, the molecular mechanisms by which LRP-1
mediates signaling are not understood [24,25]. Recently, we
found that TbR-V/LRP-1-mediated growth inhibition by IG-
FBP-3 requires insulin receptor substrate proteins (IRSs) [26].
SinceTbR-V/LRP-1 alsomediates growth inhibitionbyTGF-b1
[23], we investigated the function of IRSs in TGF-b1-induced
growth inhibition. In this communication, we demonstrate that
IRSs are involved in growth inhibition by TGF-b1.2. Materials and methods
2.1. Materials
[32P] Orthophosphate (500 mCi/ml) and [methyl-3H] thymidine (67
Ci/mmol) were purchased from ICN Biochemicals (Irvine, CA). Anti-
IRS-2 IgG was obtained from Santa Cruz Biotech (Santa Cruz, CA).
Anti-a5b1 integrin serum (rabbit) was obtained from Chemiconblished by Elsevier B.V. All rights reserved.
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(250, 148, 98, 64, 50, and 36 kDa) were obtained from Invitrogen
(Carlsbad, CA). Protein A–Sepharose was obtained from Pharmacia
LKB Biotech (Piscataway, NJ). b125(41–65), a TGF-b peptide antag-
onist, was prepared as described previously [27]. Human TGF-b1 was
purchased from Austral Biologicals (Santa Clara, CA) and R&D
Systems (Minneapolis, MN). Cyclo (GRGDSPA) was obtained from
Bachem Bioscience (King of Prussia, PA). Human IGFBP-3 (expressed
in E. coli, M.W. 35 000) and anti-IRS-2 IgG were obtained from
Upstate (Charlottesville, VA). Murine 32D myeloid cells expressing
vector only and 32D/IRS-1 and 32D/IR/IRS-2 cells, which were stably
transfected with human IRS-1 cDNA and the insulin receptor (IR)/
IRS-2 cDNAs, respectively, were provided by Dr. Martin G. Myers,
Jr., Joslin Diabetes Center, Harvard University, Boston, MA. Wild-
type 32D cells did not express IRS-1 and IRS-2 as demonstrated by
RT-PCR and immunoblot analyses [28]. 32D/IRS-1 and 32D/IR/IRS-2
cells expressed comparable levels of IRS-1 and IRS-2, respectively, as
demonstrated by immunoblot analysis [29].
2.2. 32P-metabolic labeling and immunoprecipitation
32P-metabolic labeling and immunoprecipitation of IRS-2 was per-
formed as described previously [26]. Mv1Lu cells were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM), changed to
phosphophate-free DMEM containing 0.2% of dialyzed fetal calf se-
rum for 1 h and labeled with 32P-orthophosphate (200 lC/ml) for 2 h.
They were then treated with increasing concentrations of TGF-b1 in
the presence and absence of IGFBP-3 (1 lg/ml) for 2.5 h. The cells
were lysed in RIPA buﬀer (1% sodium deoxycholate, 1% Nonidet P-40,
0.1% SDS, 25 mM Tris–HCl, pH 7.4, and 0.15 M NaCl). Equal
amounts of protein (200 lg) from the cell lysates of 32P-labeled cells
were immunoprecipitated with anti-IRS-2 IgG. The immunoprecipi-
tates were analyzed by 7.5% SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) under reducing conditions and autoradiography
(quantitated with a PhosphoImager). The 32P-labeled IRS-2 was ex-
cised from the dried gel and subjected to phosphoamino acid analysis
as described previously [20].
2.3. [Methyl-3H] thymidine incorporation assay
[Methyl-3H] thymidine incorporation assay was performed accord-
ing to our published procedures [18–21]. Mv1Lu cells were plated onFig. 1. Eﬀects of insulin on DNA synthesis in Mv1Lu cells treated with TGF-
were treated with 0.25 pM TGF-b1 in the presence of increasing concentrat
determined by measuring [methyl-3H] thymidine incorporation into cellular
nations in four independent experiments. As a positive control, Mv1Lu cells
insulin (7 nM). IGFBP-3 (0.2 lg/ml) inhibited DNA synthesis by 36% in the
treated with and without TGF-b1 (0.5 pM) insulin (10 nM) a cyclic RGD
3H] thymidine incorporation into cellular DNA was determined. The bars re
experiments. The DNA synthesis inhibition (39%) in cells treated with TG
(75%) in cells treated with TGF-b1 alone or TGF-b1 + insulin or Cyclo GR48-well clustered dishes (cell density: 1–2 105/well) and incubated
with TGF-b1 (0.25 pM) in the presence of increasing concentrations of
insulin in DMEM containing 0.2% fetal calf serum. After incubation at
37 C for 18 h, [methyl-3H] thymidine incorporation into cellular DNA
was determined as described previously [6]. 32D cells were grown in
RPMI 1640 medium containing 10% fetal calf serum and 5% WEHI
conditioned medium (which contained IL-3) [26]. These cells were
treated with increasing concentrations of TGF-b1 with or without in-
sulin (10 nM) in RPMI 1640 medium containing 0.2% fetal calf serum
and 0.05% WEHI conditioned media. After incubation at 37 C for 8
h, [methyl-3H] thymidine incorporation into cellular DNA was deter-
mined [26]. The assays were performed in quadruplicate.3. Results
3.1. Insulin partially reverses growth inhibition by TGF-b1 in
the presence of a5b1 integrin antagonists
Since insulin had been shown to reverse TbR-V/LRP-1-
mediated growth inhibition by IGFBP-3 [26], we examined
the eﬀect of insulin on TGF-b1-induced growth inhibition in
Mv1Lu cells. These cells were treated with 0.25 pM TGF-b1
in the presence of increasing concentrations of insulin. After
18 h at 37 C, DNA synthesis was determined by measuring
[methyl-3H] thymidine incorporation into cellular DNA. As
shown in Fig. 1A, insulin up to 70 nM did not signiﬁcantly
aﬀect DNA synthesis inhibition induced by 0.25 pM TGF-b1.
As a positive control, Mv1Lu cells were treated with 0.2 lg/
ml of IGFBP-3 in the presence and absence of insulin (7 nM).
IGFBP-3 (0.2 lg/ml) inhibited DNA synthesis by 36% in
these cells. This IGFBP-3-induced DNA synthesis inhibition
was completely reversed in Mv1Lu cells co-treated with in-
sulin (7 nM). These results suggest that, although TbR-V
mediates growth inhibition by both IGFBP-3 and TGF-b1,
the mechanism by which TGF-b1 induces growth inhibition is
more complex than that for IGFBP-3-induced growth inhi-b1 in the absence (A) or presence (B) of a cyclic RGD peptide. (A) Cells
ions (as indicated) of insulin. After 18 h at 37 C, DNA synthesis was
DNA. Each data point is the mean S.D. of quadruplicate determi-
were treated with 0.2 lg/ml of IGFBP-3 in the presence and absence of
se cells, which was completely reversed by 7 nM insulin. (B) Cells were
peptide (Cyclo GRGDSPA, 0.01 lg/ml) for 18 h at 37 C. The [methyl-
present means S.D. of triplicate determinations in four independent
F-b1, Cyclo GRGDSPA and insulin was signiﬁcantly less than that
GDSPA (Student’s t test, P < 0:001).
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mediated by TbR-V/LRP-1, whereas TbR-V/LRP-1 mediates
TGF-b growth inhibition in concert with TbR-I and TbR-II
[7,23,26].
Gagnon et al. [30] reported that both extracellular matrix
expression induced by TGF-b1 and ﬁbronectin impair insu-
lin-induced signal transduction by inhibiting insulin-depen-
dent IRS tyrosine phosphorylation. Thus, the ability of
insulin to block the TbR-V-mediated growth inhibitory re-
sponse to TGF-b1 may be impaired by the extracellular
matrix induced by TGF-b1 (which is mediated by the TbR-I/
TbR-II heterocomplex). To test this possibility, we examined
the eﬀect of insulin on growth inhibition by TGF-b1 (as
determined by measurement of DNA synthesis) in the
presence and absence of a cyclic RGD peptide (cyclo
GRGDSPA) [29] which blocks the binding of extracellular
matrix proteins (e.g., ﬁbronectin) to their receptors, (e.g.,
a5b1 integrin) [31]. As shown in Fig. 1B, TGF-b1 (0.5 pM)
inhibited 75% of DNA synthesis in Mv1Lu cells. Neither
insulin (10 nM) alone nor the cyclic RGD peptide (0.01 lg/
ml) alone aﬀected TGF-b1 inhibition of DNA synthesis.
However, insulin was able to partially reverse the TGF-b1
inhibition in the presence of the cyclic RGD peptide. The
combination of insulin and the cyclic RGD peptide de-
creased the TGF-b1-induced DNA synthesis inhibition from
75% to 39%. This suggests that insulin not only is ca-
pable of blocking IGFBP-3 growth inhibition [26], but also
can block growth inhibition by TGF-b1 under certain con-
ditions, such as when a cyclic RGD peptide blocks binding
of ﬁbronectin to a5b1 integrin. This suggestion is further
supported by the observation that insulin also partially re-
verses growth inhibition caused by TGF-b1 in the presence
of anti-a5b1 integrin serum. As shown in Table 1, the
combination of insulin plus anti-a5b1 integrin serum de-
creased the DNA synthesis inhibition induced by TGF-b1
from 40% to 15% in Mv1Lu cells. Neither insulin alone,
anti-a5b1 integrin serum alone nor non-immune serum aloneTable 1
Eﬀect of insulin on DNA synthesis in Mv1Lu cells treated with TGF-
b1 in the presence of anti-a5b1 integrin serum
[Methyl-3H] thymidine incorporation
cpm/well %
Control 153 811 4415 100
+TGF-b1 89 367 7307 58
+TGF-b1 + insulin 94 535 3426 61
+TGF-b1 + anti-a5b1 integrin 92 454 3943 60
+TGF-b1 + insulin+ anti-a5b1
integrin
130 493 3616 85
+insulin 154 844 2436 100
+anti-a5b1 integrin 157 983 4439 100
*Cells (5 104 cells/well) were treated with or without TGF-b1
(1 pM) insulin (10 nM) anti-a5b1 integrin serum or control non-
immune serum (400 dilution) for 18 h. DNA synthesis was deter-
mined by measuring [methyl-3H] thymidine incorporation into cellular
DNA. The [methyl-3H] thymidine incorporation in cells treated with
TGF-b1 + insulin+ non-immune serum and non-immune serum alone
were 94 483 2398 and 156 841 2349 cpm/well, respectively. The
assay was performed in quadruplicate.
** The DNA synthesis inhibition (15%) was signiﬁcantly less when
compared with that (40%) in cells treated with TGF-b1 alone or
TGF-b1 + insulin or anti-a5b1 integrin serum (Student’s t test,
P < 0:001).had any signiﬁcant eﬀect on DNA synthesis in cells treated
with or without TGF-b1.
3.2. TGF-b1 induces serine-speciﬁc phosphorylation of IRS-2 in
Mv1Lu cell
Mv1Lu cells are a standard model cell system for investi-
gating growth inhibition by TGF-b and IGFBP-3 [6,21–23,32].
Since IRS proteins are required for growth inhibition by IG-
FBP-3 and since IGFBP-3 induces serine-speciﬁc dephospho-
rylation of IRS-2 [26], it would be important to observe the
eﬀect of TGF-b1 on the phosphorylation status of IRS-2 in
these cells. As shown in Fig. 2A, TGF-b1 at 100 pM induced
phosphorylation of IRS-2 by 2-fold (lane 3 versus lane 1).
This TGF-b1-stimulated phosphorylation was inhibited by
b125(41–65), a TGF-b peptide antagonist (Fig. 2A, lane 2
versus lane 3). b125(41–65) is known to reverse TGF-b growth
inhibition by blocking TGF-b binding to TGF-b receptors
[23,26,27]. b125(41–65) alone did not inﬂuence phosphorylation
of IRS-2 (data not shown, [26]). Phosphoamino acid analysis
revealed that both TGF-b-unstimulated and -stimulated
phosphorylation occurred at serine residues as previously re-
ported [26]. Since Mv1Lu cells expressed TbR-I and TbR-II,
both of which are Ser/Thr-speciﬁc protein kinases, the TGF-
b1-induced phosphorylation may be mediated by TbR-II or
TbR-II/TbR-I complexes. To test this possibility, we examined
the eﬀect of increasing concentrations of TGF-b1 on IRS-2
phosphorylation in DR26 cells, which are Mv1Lu mutant cells
lacking functional TbR-II. As shown in Fig. 2B, increasing
concentrations of TGF-b1 correspondingly stimulated phos-
phorylation (32P-labeling) of IRS-2 in these cells (DR26 cells)
(Fig. 2B, lanes 3, 5, 8, 10 versus lane 1). Interestingly, the
TGF-b1-induced phosphorylation of IRS-2 was overridden by
IGFBP-3-induced dephosphorylation in these cells (Fig. 2B,
lanes 4, 6, 7, 9 versus lanes 3, 5, 10, 8, respectively). TheseFig. 2. TGF-b1-induced phosphorylation of IRS-2 in Mv1Lu cells (A)
and DR26 cells (B). Mv1Lu cells (A) metabolically labeled with 32P-
orthophosphate for 2 h were treated with TGF-b1 (100 pM) in the
presence or absence of b125(41–65), a TGF-b peptide antagonist (20
lM). DR26 cells (B) metabolically labeled with 32P-orthophosphate
for 2 h were treated with or without IGFBP-3 (1 lg/ml) in the presence
of increasing concentrations (0, 10, 40, 100 and 400 pM) of TGF-b1 as
indicated. After 2 h at 37 C, equal amounts of protein from the cell
lysates of 32P-labeled cells were immunoprecipitated with anti-LRP-1
serum. The immunoprecipitates were then analyzed by 7.5% SDS–
PAGE and autoradiography (quantitated with a PhosphoImager). The
arrow indicates the location of 32P-labeled IRS-2 (A). The brace in-
dicates the location of 32P-labeled IRS-2 (B). The closed and open
arrows indicate the locations of the slow or faster migrating forms of
32P-labeled IRS-2 (B).
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IRS-2 may be involved in TGF-b1-induced growth inhibition
because the TGF-b1-stimulated phosphorylation of IRS-2 is
also blocked by b125(41–65), a TGF-b peptide antagonist
which is known to reverse TGF-b growth inhibition by
blocking TGF-b binding to TGF-b receptors [7,23,26,27].
3.3. IRS proteins are involved in growth inhibition by TGF-b1
Since insulin is capable of partially reversing growth inhi-
bition by TGF-b1 in the presence of a cyclic RGD peptide or
anti-a5b1 integrin serum and since IRS proteins are required
for TbR-V-mediated growth inhibition by IGFBP-3 [26], we
hypothesized that IRS proteins are also involved in TGF-b1-
induced growth inhibition. To test this hypothesis, we ex-
amined the eﬀect of TGF-b1 on cell growth (as determined by
measurement of DNA synthesis) of 32D cells stably trans-
fected with IRS cDNAs, IR cDNA, or vector only. 32D cells
are murine myeloid cells which do not express IRS proteins
[28,33]. They express very low levels of the IR and high levels
of TbR-V ([33], unpublished results). They also respond
weakly to growth inhibition by TGF-b1 but have a functional
TbR-I/TbR-II heterocomplex-mediated signaling cascade as
determined by measurement of TGF-b1-induced transcrip-
tional activation of plasminogen activator inhibitor-1 ([26],
data not shown). For these reasons, the 32D cell system
should be appropriate for deﬁning the roles of IRS proteins in
TGF-b1 growth inhibition. As shown in Fig. 3, TGF-b1 in-
hibited DNA synthesis of 32D cells transfected with vector
only minimally (Fig. 3A). However, 32D cells expressing ei-0 5 10 15 20 250
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Fig. 3. Growth inhibition induced by TGF-b1 in 32D/IRS-1 and 32D/
IR/IRS-2 cells but not in 32D cells (A) and insulin reversal of growth
inhibition by TGF-b1 in 32D/IR/IRS-2 cells (B). Cells as indicated
were treated with increasing concentrations of TGF-b1 in the absence
(A) or presence (B) of insulin (10 nM). After 18 h at 37 C, DNA
synthesis was determined by measuring [methyl-3H] thymidine incor-
poration into cellular DNA. The [methyl-3H] thymidine incorporation
in cells treated without TGF-b1 (824 100 18 400, 384 910 10 290
and 58 051 3598 cpm/well for 32D, 32D/IRS-1 and 32D/IR/IRS-2
cells, respectively) was taken as 100% of DNA synthesis. Each data
point is the meanS.D. of quadruplicate determinations.ther IRS-1 or IRS-2 (32D/IRS-1 or 32D/IR/IRS-2 cells) ex-
hibited a robust growth inhibitory response to TGF-b1
(Fig. 3A and B). Insulin was capable of partially reversing
growth inhibition by TGF-b1 in 32D cells stably expressing
the IR and IRS-2 (32D/IR/IRS-2 cells) (Fig. 3B). These re-
sults suggest that IRS proteins are involved in growth inhi-
bition by TGF-b1.4. Discussion
TGF-b is the most potent known growth inhibitor for epi-
thelial cells [34]. Very few growth factors antagonize the
growth inhibition activity of TGF-b [1–5]. Here, we demon-
strate that insulin partially reverses growth inhibition by TGF-
b1 in the presence of a5b1 integrin antagonists in Mv1Lu cells.
Since ﬁbronectin, a prominent ligand of a5b1 integrin, has
been shown to attenuate tyrosine phosphorylation of IRS
proteins stimulated by insulin and since TGF-b stimulates the
expression of ﬁbronectin in the same cells [30], this result
suggests that: (1) the TGF-b1-stimulated expression of ﬁbro-
nectin (which is mainly mediated by the TbR-I/TbR-II/Smad2/
3/4 signaling cascade) renders Mv1Lu cells insensitive to in-
sulin-mediated reversal of TGF-b1 growth inhibition, and (2)
the TbR-I/TbR-II/Smad2/3/4 signaling cascade is capable of
regulating TbR-V-mediated signaling (which is required for
growth inhibition by TGF-b1) by positive feedback (via in-
duction of ﬁbronectin expression). This suggestion is sup-
ported by the observation that insulin partially reverses growth
inhibition by TGF-b1 in 32D/IR/IRS-2 cells. These 32D cells
do not express detectable a5b1 integrin and do not respond to
ﬁbronectin attenuation of insulin-stimulated tyrosine phos-
phorylation of IRS-2 as other cell types do ([30], data not
shown).
Two major signaling pathways are involved in the events
which follow insulin activation of the IR and the subsequent
activated IR-mediated tyrosine phosphorylation of IRS pro-
teins. These are the PI 3-kinase and MAP kinase pathways
[35,36]. These pathways do not appear to be involved in insulin-
mediated reversal of growth inhibition by either IGFBP-3 [26]
or TGF-b1 as evidenced by: (1) Insulin is capable of reversing
growth inhibition by IGFBP-3 in Mv1Lu cells treated with PI
3-kinase inhibitors (Wortmannin and LY-294002) [26,32]. (2)
Growth factors such as EGF and FGF do not reverse growth
inhibition by either IGFBP-3 or TGF-b1 [26,32]. These growth
factors are potent stimulators of the MAP kinase pathway in
Mv1Lu cells. IRS proteins are likely to be involved in growth
inhibition by IGFBP-3 and TGF-b1. We previously showed
that IRS proteins are required for growth inhibition by IGFBP-
3 [26]. Here, we demonstrate that IRS proteins are also required
for growth inhibition by TGF-b1. This is evidenced by: (1)
Insulin partially reverses growth inhibition by TGF-b1 in the
presence of a5b1 integrin antagonists (Cyclo GRGDPSA and
anti-a5b1 integrin serum), (2) stable transfection of 32Dmurine
myeloid cells (which lack expression of IRSs) with IRS-1 or
IRS-2 cDNA confers sensitivity to TGF-b growth inhibition,
and (3) insulin partially reverses TGF-b-induced growth inhi-
bition in 32D cells stably expressing IRS-2 and IR.
We recently found that insulin reverses IGFBP-3 growth
inhibition by inducing serine-speciﬁc dephosphorylation of
IRS proteins in Mv1Lu cells and mutant cells derived from
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TGF-b1 induces serine-speciﬁc phosphorylation of IRS-2 and
that this is not mediated by TbR-II because TGF-b1 is capable
of inducing such phosphorylation in DR26 cells which do not
express functional TbR-II but do express TbR-V and TbR-I.
TbR-I has been shown to be incapable of binding ligands in
the absence of TbR-II [11,12]. The ability of TbR-V to mediate
such distinct activities (dephosphorylation and phosphoryla-
tion) upon IGFBP-3 and TGF-b1 binding (in Mv1Lu and
DR26 cells) is intriguing. TbR-V may form diﬀerent complexes
with plasma membrane proteins (e.g., co-receptors) and cyto-
plasmic proteins (e.g., protein kinases and phosphatases),
which respond diﬀerently to IGFBP-3 or TGF-b1 binding as
measured by the downstream eﬀects on the phosphorylation
status of IRS proteins. There are three lines of evidence to
support this possibility: (1) IGFBP-3 and TGF-b1 bind to
distinct sites in the TbR-V molecules (unpublished results). (2)
LRP-1, which is identical to TbR-V, has been shown to be a
component of signaling complexes containing protein phos-
phatases or kinases [37–42]. (3) Most of the TbR-V in Mv1Lu
cells is not required for the growth inhibitory response to
IGFBP-3 and TGF-b1 [23]. Mutagenized Mv1Lu cells selected
for reduced expression (6 5%) of the TbR-V still respond to
growth inhibition by IGFBP-3 and TGF-b1 although the
growth inhibitory response in these Mv1Lu mutant cells is
attenuated [23]. This evidence supports the view that TbR-V
exists in heterogeneous populations and that only a small
fraction of cell-surface TbR-V is required to mediate the
growth inhibitory response.
The ﬁnding of cross talk (via IRS proteins) between the in-
sulin-induced signaling and TGF-b-induced (TbR-V/LRP-1-
mediated) growth inhibitory signaling cascades has potential
clinical implications. Insulin or insulin signaling defects may
up-regulate the TGF-b activity generated in wounds, resulting
in the attenuation of wound re-epithelialization and healing
[43], which is a common clinical problem observed particularly
often in diabetic patients.
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